Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be able to understand and sign a consent form agreeing to take part in the trial.
- You must be between 18 and 80 years old.
- You must be reasonably active and able to carry out daily activities with little or no limitation (confirm with trial site regarding exact fitness level required).
- You must be expected to live for more than 6 months.
- Your prostate cancer must have been confirmed through a tissue or cell sample test.
- You must have had a specific type of scan (called a PSMA PET/CT scan) that showed a positive result.
- Your testosterone levels must be at a very low level, consistent with being on hormone-suppressing treatment.
- You must have already been treated with at least one specific type of hormone-blocking drug (such as enzalutamide or abiraterone), and either had at least one or two courses of a chemotherapy type called taxane, or been found unsuitable for that chemotherapy for medical reasons or by personal choice.
- Your prostate cancer must be continuing to grow or spread despite treatment (known as metastatic castration-resistant prostate cancer, or mCRPC).
- Your kidneys, liver, and other organs must be working well enough to take part.
- If you are capable of having children, you must agree to use effective contraception during the trial and for 6 months after the last dose of the trial drug.
Who may not be able to join:
- You have received certain types of radiation treatments (such as Radium-223 or similar bone-targeting therapies) within the last 6 months, or have ever had a PSMA-targeted radiation therapy before.
- You have been diagnosed with another type of cancer.
- You have had any cancer treatment (such as chemotherapy or immunotherapy) within the last 28 days before joining.
- You have a known allergy or sensitivity to the trial drug or similar medicines.
- A bone scan taken before the trial shows a particular pattern of widespread bone involvement (confirm with trial site).
- You have a history of cancer spreading to the brain or spinal cord.
- You have another serious, uncontrolled illness, such as an active infection, heart failure, or irregular heartbeat.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jinming Zhang, The First Medical Center, Chinese PLA General Hospital
Phone: (+86)010-66936108
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1.Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; Dose-limiting toxicity（DLT）; Whole body and organ uptake of [177Lu]Lu-PSMA-XT Injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.